Romosozumab and Sequential Therapy in Postmenopausal Osteoporosis

Area of Science:

• Osteoporosis Research
• Pharmacological Interventions
• Bone Metabolism

Background:

• Postmenopausal osteoporosis poses a significant fracture risk.
• Existing treatments may have limitations for some patients.
• Romosozumab offers a novel mechanism targeting bone remodeling.

Purpose of the Study:

• To review sequential romosozumab therapy effects in postmenopausal women.
• To assess impacts on bone turnover, bone mineral density (BMD), and fractures.
• To synthesize evidence from controlled clinical trials.

Main Methods:

• Systematic literature search of PubMed and International Pharmaceutical Abstracts.
• Inclusion of controlled clinical trials evaluating sequential romosozumab therapy.
• Exclusion of studies not assessing romosozumab before or after other osteoporosis treatments.

Main Results:

• Romosozumab, a sclerostin inhibitor, increases bone formation and decreases resorption.
• Sequential romosozumab therapy led to reduced bone resorption markers.
• Improvements in bone formation markers, BMD, and reduced clinical fracture risk were observed.

Conclusions:

• Sequential romosozumab therapy is effective in improving bone health markers and reducing fractures in postmenopausal women.
• Efficacy must be balanced against an increased risk of cardiovascular adverse events.
• Further evaluation of risk-benefit profiles in diverse patient populations is warranted.